Clinical trial
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic…
NCT00096109 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00096109 |
|---|---|
| Title | Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer |
| Official title | A Phase II Clinical Trial of 17-Allyamino-17-Demethoxygeldanamycin (17-AAG) in Chemotherapy Refractory Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | tanespimycin, laboratory biomarker analysis |
| Enrollment | 11 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2012 |
| Completion | May 1, 2012 |
| First posted | Nov 9, 2004 |
| Last update posted | Jan 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: